J
Jeffrey D. Bornstein
Researcher at Takeda Pharmaceutical Company
Publications - 8
Citations - 771
Jeffrey D. Bornstein is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Vedolizumab & Adalimumab. The author has an hindex of 5, co-authored 8 publications receiving 674 citations.
Papers
More filters
Journal ArticleDOI
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Stephan R. Targan,Brian G. Feagan,Richard N. Fedorak,Bret A. Lashner,Remo Panaccione,Daniel H. Present,Martina E. Spehlmann,Paul Rutgeerts,Zsolt Tulassay,Miroslava Volfova,Douglas C. Wolf,Chito Hernandez,Jeffrey D. Bornstein,William J. Sandborn +13 more
TL;DR: Response and remission rates for natalizumab were superior to those for placebo at Weeks 4, 8, and 12, demonstrating the early and sustained efficacy of natalIZumab as induction therapy in patients with elevated C-reactive protein and active Crohn's disease.
Journal ArticleDOI
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn’s Disease
Silvio Danese,William J. Sandborn,Jean-Frederic Colombel,Severine Vermeire,Sarah C. Glover,Jordi Rimola,Jenifer Siegelman,S Jones,Jeffrey D. Bornstein,Brian G. Feagan +9 more
TL;DR: In a phase 3b trial, it is found that 26 and 52 weeks of treatment with vedolizumab induces endoscopic, radiologic, and histologic healing in patients with moderately to severely active Crohn's disease.
Journal ArticleDOI
OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis
Stefan Schreiber,Laurent Peyrin-Biroulet,Edward V. Loftus,Silvio Danese,Jean-Frederic Colombel,Brihad Abhyankar,Jingjing Chen,Raquel Rogers,Richard A. Lirio,Jeffrey D. Bornstein,Bruce E. Sands +10 more
Journal ArticleDOI
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
Laurent Peyrin-Biroulet,Edward V. Loftus,Jean-Frederic Colombel,Silvio Danese,Raquel Rogers,Jeffrey D. Bornstein,Jingjing Chen,Stefan Schreiber,Bruce E. Sands,Richard A. Lirio +9 more
TL;DR: Vedolizumab vs. adalimumab as discussed by the authors showed superior clinical remission and endoscopic improvement in patients with ulcerative colitis compared to the traditional subcutaneous anti-TNF-naive and -failure subgroups.
Journal ArticleDOI